Immatics N.V. (NASDAQ:IMTX) Receives $19.20 Consensus PT from Brokerages

Immatics N.V. (NASDAQ:IMTX) has been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $19.20.

A number of brokerages have recently weighed in on IMTX. Chardan Capital reissued a “buy” rating and set a $25.00 price target on shares of Immatics in a research report on Monday, November 24th. Guggenheim raised their price objective on Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research note on Thursday, January 22nd. Wall Street Zen downgraded Immatics from a “hold” rating to a “sell” rating in a report on Sunday. Finally, Leerink Partners reiterated an “outperform” rating and set a $17.00 price objective on shares of Immatics in a report on Thursday, December 4th.

Hedge Funds Weigh In On Immatics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its stake in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares during the period. Quarry LP acquired a new stake in Immatics in the 4th quarter valued at approximately $84,000. Insigneo Advisory Services LLC bought a new stake in Immatics in the 3rd quarter valued at approximately $103,000. Engineers Gate Manager LP bought a new stake in Immatics in the 2nd quarter valued at approximately $124,000. Finally, Fox Run Management L.L.C. acquired a new position in Immatics during the 4th quarter worth approximately $129,000. 64.41% of the stock is owned by institutional investors and hedge funds.

Immatics Price Performance

Immatics stock opened at $10.34 on Friday. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -10.14 and a beta of 1.34. The company’s 50 day simple moving average is $9.91 and its 200 day simple moving average is $9.07. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $12.41.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.